Reviewed by Dr. Elena Vance, DOLast reviewed 4 sources cited
Quick Summary
Bydureon BCise (exenatide) and Rybelsus (semaglutide) are both glp-1 receptor agonists. In clinical trials, Rybelsus showed greater weight loss (4.4% vs 2.3%).
See the comparison table below for detailed side-by-side data.
Bydureon BCise vs Rybelsus: Full Comparison
| Feature | Bydureon BCise(exenatide extended-release) | Rybelsus(semaglutide) |
|---|---|---|
| Active Ingredient | exenatide | semaglutide |
| Drug Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | AstraZeneca | Novo Nordisk |
| FDA Approved | 2012-01-27 | 2019-09-20 |
| Approved Indications |
|
|
| Route | subcutaneous injection | oral |
| Frequency | Once weekly | Once daily |
| Starting Dose | 2 mg weekly | 3 mg daily |
| Maintenance Dose | 2 mg weekly | 7 mg or 14 mg daily |
| Max Dose | 2 mg weekly | 14 mg daily |
| Weight Loss (%) | 2.3% | 4.4% |
| A1C Reduction | 1.3% | 1.4% |
| Key Trial | DURATION-1 (30 weeks) | PIONEER 1 (26 weeks) |
| List Price | $800-$950/month | $935-$1,029/month |
| With Insurance | $25-$100/month (varies by plan) | $25-$150/month (varies by plan) |
| Savings Card | Limited savings programs available | $10/month (Novo Nordisk savings card, commercially insured) |
Side Effects: Bydureon BCise vs Rybelsus
| Side Effect | Bydureon BCise | Rybelsus |
|---|---|---|
| Nausea | 11% | 11-20% |
| Diarrhea | 9% | 5-10% |
| Injection site nodule | 10-17% | Not reported |
| Headache | 8% | Not reported |
| Vomiting | 4% | 4-8% |
| Constipation | 6% | 3-5% |
| Pancreatitis (rare) | <1% | <0.5% |
| Abdominal pain | Not reported | 5-11% |
| Decreased appetite | Not reported | 3-9% |
Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.
Related Comparisons
Frequently Asked Questions
Sources & References
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.